https://www.idival.org/wp-content/uploads/2022/05/cab-presentacion.jpg

Second session Valdecilla Progress Reports

10 de December de 2017

The second session of the program of lectures Valdecilla Progress Reports will take place on December 13 and it will be given by Maria Kislikova and Arantza Onaindia who will present their scientific advances of their current projects.  Maria Kislikova is a specialist in nephrology at the University Hospital Marqués de Valdecilla and she gained […]

Read more →

A successful Science Week 2017

Once again, the Valdecilla Research Institute has opened its doors to the students of Cantabria during the Science Week, held from November 6 to 17. Science Week is an activity of scientific and informative nature that is carried out simultaneously in all Research Centers and the University of Cantabria. IDIVAL's microbiology laboratory has received more […]

Read more →

Conference IDIVAL perspectives of present and future

For several reasons, Prof. Jordi Vila cannot attend to Santander Biomedical Lectures conference tomorrow, November 30th. The occasion will be used to present the results obtained from Marqués de Valdecilla Research Institute (IDIVAL) during this year and offer perspectives for the future. The conference will be given by the Management Director, Galo Peralta Fernández and […]

Read more →

La Caixa health research call for proposals

30 de November de 2017

The “La Caixa” Banking Foundation is launching a new call for applications for biomedicine and health research project grants with a view to identifying and promoting the most promising initiatives of scientific excellence with the greatest value, potential and social impact. The research projects may be basic, clinical or translational. This new call will take […]

Read more →

IDIVAL creates a brain bank

19 de November de 2017

Marqués de Valdecilla University Hospital and the Biomedical Research Institute (IDIVAL) have set in motion a brain bank to collect, process, store and transfer biological samples donated by patients and individuals without neurological pathology to be used in research projects. This brain bank is coordinated by Dr. Nuria Terán, from the Pathological Anatomy Unit, and […]

Read more →

The European Commission has published the Working Progremmes for Horizon 2020 during 2018-2020

13 de November de 2017

The European Commission  has announced how it will spend €30 billion of the EU research and innovation funding programme Horizon 2020 during 2018-2020. The working programme detail the research priorities that will be financed in the calls for proposals. In the Participant Portal, you can consult the Working Programs and the detail of the calls for proposals […]

Read more →

II Edition course guidelines in good clinical practice

11 de November de 2017

The Biomedical Research Institute Marqués de Valdecilla (IDIVAL) organizes the II edition of the course “Guidelines in Good Clinical Practice” directed to all the medical personnel of Cantabria that are interested in clinical investigation. The course will take place from the 27th of November to the 1st of December. With this training activity, IDIVAL is […]

Read more →

Conference Clinicopathological classification of neurodegenerative diseases

Gabor G. Kovacs is Associate Professor in the Institute of Neurology, Medical University of Vienna, Austria. After receiving his MD degree, his work has been devoted to neurology and neuropathology, i.e. the study of tissue alterations in diseases of the nervous system for diagnostic and research purposes. Gabor G. Kovacs is working on the Surveillance […]

Read more →

One more year IDIVAL takes part in the Science Week

1 de November de 2017

IDIVAL Clinical and Molecular Microbiology group will participate in the Science Week, one of the most important scientific events of the year in Europe. On days 6, 9, and 16 of November, IDIVAL will be open to the Cantabrian high school students, to show their daily work in an attractive way, in which students can […]

Read more →

Complete response under sorafenib in patients with hepatocellular carcinoma

Sorafenib is the principal (and until recently the only) first-line systemic treatment for patients with advanced hepatocellular carcinoma (HCC). Despite having been shown to improve survival in 2 randomized clinical trials compared with placebo [Llovet JM et al. N Engl J Med. 2008; 359: 378-90 and Chen A-L et al. Lancet Oncol. 2009; 10: 25-34] […]

Read more →